MCID: LVR012
MIFTS: 67

Liver Cirrhosis malady

Categories: Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Liver Cirrhosis

Aliases & Descriptions for Liver Cirrhosis:

Name: Liver Cirrhosis 38 12 52 42 14 69
Cirrhosis 12 29 52 41 14 69
Cirrhosis of Liver 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5082
ICD10 33 K74.60
MeSH 42 D008103
NCIt 47 C2951
UMLS 69 C0023890

Summaries for Liver Cirrhosis

MedlinePlus : 41 cirrhosis is scarring of the liver. scar tissue forms because of injury or long-term disease. scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. cirrhosis can lead to easy bruising or bleeding, or nosebleeds swelling of the abdomen or legs extra sensitivity to medicines high blood pressure in the vein entering the liver enlarged veins called varices in the esophagus and stomach. varices can bleed suddenly. kidney failure jaundice severe itching gallstones a small number of people with cirrhosis get liver cancer. your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. cirrhosis has many causes. in the united states, the most common causes are chronic alcoholism and hepatitis. nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. if too much scar tissue forms, you may need to consider a liver transplant. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Liver Cirrhosis, also known as cirrhosis, is related to obstructive jaundice and membranoproliferative glomerulonephritis, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Liver Cirrhosis is ALB (Albumin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and NRF2 pathway. The drugs Adefovir Dipivoxil and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood, and related phenotypes are homeostasis/metabolism and hematopoietic system

Related Diseases for Liver Cirrhosis

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 328)
id Related Disease Score Top Affiliating Genes
1 obstructive jaundice 29.9 ALB EDN1 F2 SERPINC1
2 membranoproliferative glomerulonephritis 29.8 ALB F2 SERPINC1 TF THPO
3 bacterial meningitis 29.7 ALB F2 GGT1 GPT
4 pericarditis 29.5 ALB EDN1 REN SERPINC1
5 myocardial infarction 29.3 ALB EDN1 F2 HFE NPPA REN
6 alcoholic liver cirrhosis 12.3
7 primary biliary cirrhosis 11.7
8 cirrhosis, cryptogenic 11.5
9 budd-chiari syndrome 11.1
10 pulmonary arteriovenous malformation 11.1
11 deafness-lymphedema-leukemia syndrome 10.7
12 cholangitis, primary sclerosing 10.7
13 glycogen storage disease iv 10.7
14 dyskeratosis congenita, autosomal recessive 1 10.7
15 mitochondrial dna depletion syndrome 4a 10.7
16 hemochromatosis, type 2a 10.7
17 dyskeratosis congenita, x-linked 10.7
18 wolman disease 10.7
19 hepatitis 10.7
20 hepatocellular carcinoma 10.6
21 nondystrophic myotonia 10.4 ALB F2
22 polycystic echinococcosis 10.4 F2 TF
23 infiltrating ureter transitional cell carcinoma 10.4 ALB F2 SLC17A5
24 freiberg's disease 10.4 ALB F2 SERPINC1
25 ebstein anomaly 10.4 GGT1 SLC17A5
26 hepatitis b 10.4
27 eagle syndrome 10.4 ALB F2 SERPINC1
28 atrophic vulva 10.4 ALB F2 TGFB1
29 gastric neuroendocrine tumor type 1 10.4 GPT SLC17A5
30 rosacea 10.4 ALB GPT SLC17A5
31 dermatoleukodystrophy 10.4 HFE TF
32 mixed hepatoblastoma 10.4 F2 SERPINC1 TGFB1
33 influenza 10.4 F2 REN SERPINC1
34 malignant hyperthermia susceptibility 1 10.4 ALB SERPINC1 TF
35 epstein-barr virus hepatitis 10.4 F2 NPPA SERPINC1
36 cataract 10.4 ALB HGF SERPINC1
37 benign deep fibrous histiocytoma 10.4 ALB F2 GPT
38 ischemic optic neuropathy 10.4 ALB F2 SERPINC1
39 familial progressive hyperpigmentation 10.4 F2 GPT
40 pyelitis 10.4 ALB F2 GPT
41 bladder sarcoma 10.4 ALB GPT TF
42 uterine inflammatory disease 10.4 EDN1 REN
43 fallopian tube leiomyosarcoma 10.4 ALB F2 GPT
44 idiopathic juvenile osteoporosis 10.3 ALB HGF NPPA
45 kohler's disease 10.3 ALB F2 GPT SLC17A5
46 hepatitis c 10.3
47 congenital hypoplastic anemia 10.3 ALB F2 GPT SLC17A5
48 petrositis 10.3 ALB EDN1 REN
49 episcleritis periodica fugax 10.3 GPT HFE TF
50 vulvar sarcoma 10.3 ALB SERPINA1 TGFB1

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis

Symptoms & Phenotypes for Liver Cirrhosis

UMLS symptoms related to Liver Cirrhosis:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, hepatosplenomegaly, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Liver Cirrhosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 AFP ALB CYP2E1 EDN1 F2 GGT1
2 hematopoietic system MP:0005397 10.1 F2 GGT1 GPC3 GPT HFE HGF
3 mortality/aging MP:0010768 9.8 ALB CYP2E1 EDN1 F2 GGT1 GPC3
4 liver/biliary system MP:0005370 9.7 AFP ALB CYP2E1 HFE HGF SERPINC1
5 renal/urinary system MP:0005367 9.23 ALB EDN1 GGT1 GPC3 NPPA REN

Drugs & Therapeutics for Liver Cirrhosis

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 683)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 1,Phase 2 142340-99-6 60871
2
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2 3424-98-4 159269
3
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
4
Cefoxitin Approved Phase 4 35607-66-0 441199
5
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
6
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Early Phase 1 85721-33-1 2764
7
Losartan Approved Phase 4,Phase 3 114798-26-4 3961
8
Magnesium oxide Approved Phase 4 1309-48-4 14792
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
10
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
11
Imipenem Approved Phase 4 74431-23-5 104838
12
Vancomycin Approved Phase 4 1404-90-6 441141 14969
13
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 80621-81-4 6436173
14
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2 525-66-6 4946
15
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
16
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
17
Entecavir Approved, Investigational Phase 4,Phase 1,Phase 2 142217-69-4 153941
18
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
19
Tenofovir Approved, Investigational Phase 4,Phase 3 147127-20-6 464205
20
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
21
Insulin Glargine Approved Phase 4 160337-95-1
22
Insulin-glulisine Approved Phase 4 207748-29-6
23
Zinc Approved Phase 4 7440-66-6 32051 23994
24
Menthol Approved Phase 4,Phase 3,Phase 1 2216-51-5 16666
25
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
26
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
27
Lactulose Approved Phase 4,Phase 3,Phase 2 4618-18-2 11333
28
Colchicine Approved Phase 4,Phase 3,Phase 1 64-86-8 6167 2833
29
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2 99210-65-8, 215647-85-1
30
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 83150-76-9 383414 6400441
31
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
32
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3 14636-12-5 72081
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1 437-38-7 3345
34
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
35
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
36
Tolvaptan Approved Phase 4,Phase 2,Phase 3,Phase 1 150683-30-0 216237
37
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
38
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
39
Prazosin Approved Phase 4,Phase 2 19216-56-9 4893
40
Carboplatin Approved Phase 4,Phase 2,Phase 3 41575-94-4 10339178 498142 38904
41
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
42
Ethiodized oil Approved Phase 4,Phase 3,Phase 2,Phase 1 8008-53-5
43
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 284461-73-0 216239 406563
44
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
45
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
46
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
47
Bisacodyl Approved Phase 4 603-50-9
48
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128-13-2 31401
49
Midodrine Approved Phase 4,Phase 2,Phase 3 133163-28-7, 42794-76-3 4195
50
Norfloxacin Approved Phase 4,Phase 3,Phase 2 70458-96-7 4539

Interventional clinical trials:

(show top 50) (show all 1569)
id Name Status NCT ID Phase
1 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4
2 Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis Unknown status NCT01265173 Phase 4
3 Prevention of Decompensation in Liver Cirrhosis Unknown status NCT00239096 Phase 4
4 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4
5 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
6 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4
7 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4
8 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4
9 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4
10 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4
11 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4
12 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4
13 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4
14 Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline Unknown status NCT00343122 Phase 4
15 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4
16 Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding Unknown status NCT00965900 Phase 4
17 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4
18 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4
19 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Unknown status NCT01059396 Phase 4
20 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4
21 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4
22 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
23 Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding Unknown status NCT00966355 Phase 4
24 Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol for the Prevention of Variceal Rebleeding Unknown status NCT00966121 Phase 4
25 Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol for the Prevention of Variceal Rebleeding in Pts With Previous Variceal Treatment Unknown status NCT00966082 Phase 4
26 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4
27 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
28 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4
29 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4
30 Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker Unknown status NCT01298271 Phase 4
31 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4
32 Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients Unknown status NCT00906139 Phase 4
33 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4
34 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4
35 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
36 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
37 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4
38 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
39 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4
40 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4
41 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4
42 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4
43 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4
44 Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients Unknown status NCT01853709 Phase 4
45 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
46 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
47 Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection Completed NCT02414880 Phase 4
48 Enteral Nutrition in Liver Cirrhosis Completed NCT00168961 Phase 4
49 Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
50 Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis Completed NCT01686698 Phase 4

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver cirrhosis

Genetic Tests for Liver Cirrhosis

Genetic tests related to Liver Cirrhosis:

id Genetic test Affiliating Genes
1 Cirrhosis 29

Anatomical Context for Liver Cirrhosis

MalaCards organs/tissues related to Liver Cirrhosis:

39
Liver, Bone, Testes, Kidney, Bone Marrow, Endothelial, Spleen
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
id Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Liver Cirrhosis

Articles related to Liver Cirrhosis:

(show top 50) (show all 1563)
id Title Authors Year
1
N-Terminal pro-B-Type Natriuretic Peptide Levels are Linked with Modified Child-Pugh Classification in Patients with Nonalcoholic Cirrhosis [NT-ProBNP and Liver Cirrhosis]. ( 27914003 )
2017
2
Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. ( 28052155 )
2017
3
Up to date of therapeutic approach for liver cirrhosis. ( 28070098 )
2017
4
Acoustic radiation force impulse elastography: comparison and combination with other noninvasive tests for the diagnosis of compensated liver cirrhosis. ( 28067683 )
2017
5
Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. ( 28070704 )
2017
6
Effect of Yi Guan Jian decoction on differentiation of bone marrow mesenchymalstem cells into hepatocyte-like cells in dimethylnitrosamine-induced liver cirrhosis in mice. ( 28035356 )
2017
7
Impact of genetic variation in the vasopressin 1a receptor on the development of organ failure in patients admitted for acute decompensation of liver cirrhosis. ( 28079670 )
2017
8
Current status and issues of liver transplantation for decompensated liver cirrhosis. ( 28070093 )
2017
9
Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls. ( 27657935 )
2016
10
Prevalence, Risk Factors and In-hospital Outcomes of QTc Interval Prolongation in Liver Cirrhosis. ( 27650234 )
2016
11
Predicting stroke volume and arterial pressure fluid responsiveness in liver cirrhosis patients using dynamic preload variables: A prospective study of diagnostic accuracy. ( 27167058 )
2016
12
Epidemiology of bacterial infections in patients with liver cirrhosis. Experience in a Spanish tertiary health center. ( 27622445 )
2016
13
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. ( 27026379 )
2016
14
Living donor liver transplantation indicated for compensated liver cirrhosis with symptomatic gallstone diseases: report of two cases. ( 27215224 )
2016
15
Hepatic enhancement of Gd-EOB-DTPA-enhanced 3 Tesla MR imaging: Assessing severity of liver cirrhosis. ( 27197633 )
2016
16
Being an informal caregiver for a relative with liver cirrhosis and overt hepatic encephalopathy: a phenomenological study. ( 27167534 )
2016
17
[(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. ( 27164900 )
2016
18
Length of Variable Numbers of Tandem Repeats in the Carboxyl Ester Lipase (CEL) Gene May Confer Susceptibility to Alcoholic Liver Cirrhosis but Not Alcoholic Chronic Pancreatitis. ( 27802312 )
2016
19
Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis. ( 27626413 )
2016
20
Frequency of Hepatopulmonary Syndrome (HPS) Among Patients With Liver Cirrhosis: A Letter to Editor. ( 27148388 )
2016
21
Uncommon cause of acute encephalopathy in liver cirrhosis. ( 27194673 )
2016
22
Th2 Dominance Might Induce Carcinogenesis in Patients with HCV-related Liver Cirrhosis. ( 27630292 )
2016
23
Role of estrogen receptor I^ selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis. ( 27182159 )
2016
24
Henoch-SchAPnlein purpura nephritis and colitis in an adult patient with alcoholic liver cirrhosis. ( 27668165 )
2016
25
Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver Cirrhosis. ( 27213061 )
2016
26
Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. ( 27034286 )
2016
27
Techniques of TIPS in the treatment of liver cirrhosis combined with incompletely occlusive main portal vein thrombosis. ( 27620282 )
2016
28
LC-PROM: Validation of a patient reported outcomes measure for liver cirrhosis patients. ( 27165036 )
2016
29
Liver Cirrhosis and Kidney. ( 27170393 )
2016
30
A novel glycobiomarker, Wisteria floribunda agglutinin macrophage colony-stimulating factor receptor, for predicting carcinogenesis of liver cirrhosis. ( 26437001 )
2016
31
Splenectomy versus Partial Splenic Embolization for Massive Splenomegaly Secondary to Hepatitis B-Related Liver Cirrhosis: A Case-Control Study. ( 27418925 )
2016
32
Hemodynamic response to primary prophylactic therapy with nonselective I^-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. ( 28002118 )
2016
33
Concentrations of fetuin-A, osteoprotegerin and I+-Klotho in patients with alcoholic liver cirrhosis. ( 27882180 )
2016
34
Hyperhomocysteinemia and MTHFR C677T polymorphism in patients with portal vein thrombosis complicating liver cirrhosis. ( 27065203 )
2016
35
Serum Concentrations of Selected Heavy Metals in Patients with Alcoholic Liver Cirrhosis from the Lublin Region in Eastern Poland. ( 27304961 )
2016
36
Behavior of Oxidative Stress Markers in Alcoholic Liver Cirrhosis Patients. ( 28074118 )
2016
37
Doppler Ultrasound in Liver Cirrhosis: Correlation of Hepatic Artery and Portal Vein Measurements With Model for End-Stage Liver Disease Score. ( 28026900 )
2016
38
IL-17A up-regulates expression of endothelial tissue factor in liver cirrhosis via the ROS/p38 signal pathway. ( 26742425 )
2016
39
CLIF-SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis. ( 27367990 )
2016
40
Secondary sclerosing cholangitis rapidly leading to liver cirrhosis: a possible post-ICU treatment sequel. ( 26092685 )
2016
41
Pharmacokinetics of New HCV NS3 Protease Inhibitor Narlaprevir Following Single Dose Use with or without Ritonavir in patients with liver cirrhosis. ( 27645244 )
2016
42
IL10 rs1800896 polymorphism is associated with liver cirrhosis and chronic hepatitis B. ( 26909998 )
2016
43
Glucose fluctuations reduce quality of sleep and of life in patients with liver cirrhosis. ( 27624504 )
2016
44
Hyperammonemia Is Associated with Increasing Severity of Both Liver Cirrhosis and Hepatic Encephalopathy. ( 27847646 )
2016
45
The role of serum procalcitonin and C-reactive protein levels in predicting spontaneous bacterial peritonitis in patients with advanced liver cirrhosis. ( 28083050 )
2016
46
Erratum to: Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. ( 27662883 )
2016
47
Identification and clinical significance of an elevated level of serum aminoacylase-1 autoantibody in patients with hepatitis B virus-related liver cirrhosis. ( 27633755 )
2016
48
Umbilical hernia in patients with liver cirrhosis: A surgical challenge. ( 27462389 )
2016
49
Aldehyde Dehydrogenase 2 (ALDH2) Polymorphism and the Risk of Alcoholic Liver Cirrhosis among East Asians: A Meta-Analysis. ( 27189280 )
2016
50
A two-layer model to identify hepatitis B virus related chronic hepatitis and liver cirrhosis based on plasma microRNA biomarkers. ( 28000564 )
2016

Variations for Liver Cirrhosis

Copy number variations for Liver Cirrhosis from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis

Expression for Liver Cirrhosis

Search GEO for disease gene expression data for Liver Cirrhosis.

Pathways for Liver Cirrhosis

GO Terms for Liver Cirrhosis

Cellular components related to Liver Cirrhosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 AFP ALB EDN1 F2 GPC3 HGF
2 blood microparticle GO:0072562 9.77 ALB F2 SERPINC1 TF TGFB1
3 endoplasmic reticulum lumen GO:0005788 9.7 AFP ALB F2 GPC3 SERPINA1 SERPINC1
4 platelet alpha granule lumen GO:0031093 9.56 ALB HGF SERPINA1 TGFB1
5 extracellular space GO:0005615 9.55 AFP ALB EDN1 F2 GGT1 GPC3
6 basal part of cell GO:0045178 9.5 EDN1 HFE TF
7 HFE-transferrin receptor complex GO:1990712 9.4 HFE TF

Biological processes related to Liver Cirrhosis according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.76 F2 IFNA1 SERPINA1 SERPINC1
2 female pregnancy GO:0007565 9.67 HFE NPPA TGFB1
3 regulation of blood pressure GO:0008217 9.65 EDN1 NPPA REN
4 post-translational protein modification GO:0043687 9.63 AFP ALB GPC3 SERPINA1 SERPINC1 TF
5 hemostasis GO:0007599 9.58 F2 SERPINA1 SERPINC1
6 cellular response to iron ion GO:0071281 9.43 HFE TF
7 acute-phase response GO:0006953 9.43 F2 HFE SERPINA1
8 response to ozone GO:0010193 9.37 CYP2E1 EDN1
9 platelet degranulation GO:0002576 9.35 ALB HGF SERPINA1 TF TGFB1
10 positive regulation of odontogenesis GO:0042482 9.32 EDN1 TGFB1
11 cellular protein metabolic process GO:0044267 9.23 AFP ALB F2 GPC3 NPPA SERPINA1

Molecular functions related to Liver Cirrhosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 EDN1 IFNA1 TGFB1 THPO
2 receptor binding GO:0005102 9.35 EDN1 F2 HFE NPPA REN
3 transferrin receptor binding GO:1990459 9.16 HFE TF
4 growth factor activity GO:0008083 8.92 F2 HGF TGFB1 THPO

Sources for Liver Cirrhosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....